flow cytometry

2:12
Monitoring disease in high-risk MM: Euroflow with mass spectrometry
Andrew Spencer
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay
3:53
Comparison of MRD and conventional IMWG response assessment in the GEM-CESAR trial
Noemí Puig
2:20
Should we act therapeutically on MRD positivity in AML?
Christoph Röllig
1:44
Is MRD ready for clinical practice?
Lydia Scarfò
3:19
Sample size limitations in MRD
Thomas Kipps
23:38
MRD evaluation: a key component of MM management?
Elena Zamagni et al.
2:43
The value of MRD assessment in CLL
Arnon Kater
1:25
Coupling imaging and molecular techniques to determine MRD in MM
Elena Zamagni
1:47
Depth of MRD assessment in MM
Graham Jackson
3:35
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Sasanka Handunnetti
3:21
Developments in acute leukemias: biology, therapeutics and monitoring
Richard Stone
1:52
MRD by flow cytometry
Giuseppe Gaipa
4:59
Checkpoint Inhibitors in AML
Naval Daver
5:35
Advanced flow cytometry & CAR-T for the treatment of acute leukemias
Giuseppe Gaipa
2:22
Molecular MRD detection in AML
Peter Valk
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals